FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis